Icon expands clinical trial technology platform
Medical imaging core lab services provider Icon Medical Imaging has expanded its technology platform to expedite oncology clinical trials, incorporating RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 evaluation criteria to its ICOSpeedRead system.
The ICOSpeedRead supports the review of medical images in oncology clinical trials, said the Dublin-based company. With the addition of RECIST, criteria for studies with imaging endpoints, such as progression-free survival and tumor response will be applied.
The ICOSpeedRead supports the review of medical images in oncology clinical trials, said the Dublin-based company. With the addition of RECIST, criteria for studies with imaging endpoints, such as progression-free survival and tumor response will be applied.